Sosei Group Corporation SOLTF today announces that its
wholly-owned subsidiary, Heptares Therapeutics has entered into a
strategic drug discovery collaboration with Pfizer Inc. PFE to
research and develop potential new medicines directed at up to 10 G
protein-coupled receptor (GPCR) targets across multiple therapeutic
areas.
Heptares will use its proprietary GPCR structure-guided platform to help
deliver stabilised GPCRs (StaR® proteins), high-resolution
crystal structures and other technologies to support the discovery of
potential novel agents directed to the GPCR targets selected by Pfizer.
Pfizer will be responsible for developing and commercialising any
potential therapeutic agents (small molecules or biologics derived from
StaR antigens) for each target and will have
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in